Frontotemporal dementia (FTD) is a progressive brain disorder that primarily affects the frontal and temporal lobes, leading to personality changes, language difficulties, and behavioral disturbances. As per Xinxin Chen et al., 2024, FTD accounts for 10-20% of all dementia cases. The frontotemporal dementia drug pipeline is gaining momentum with several therapies under development targeting tau proteins and genetic mutations. According to the frontotemporal dementia pipeline analysis by Expert Market Research, the growing focus on disease-modifying treatments, increased R&D investments, and improved diagnostic techniques are expected to drive significant market growth in the coming years.
Major companies involved in the frontotemporal dementia pipeline analysis include Alector Inc., GlaxoSmithKline, and others.
Leading drugs currently in the pipeline include AL001, LY3884963, VES001, and others.
The frontotemporal dementia based drug pipeline is poised for growth, driven by increased biomarker research, rising clinical trial activity, and expanding focus on tau-targeting and gene therapy-based treatments.
The Frontotemporal Dementia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into frontotemporal dementia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for frontotemporal dementia. The frontotemporal dementia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The frontotemporal dementia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with frontotemporal dementia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to frontotemporal dementia.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Frontotemporal dementia (FTD) is a rare neurodegenerative condition that primarily affects the frontal and temporal lobes of the brain, leading to changes in behavior, personality, and language. It occurs due to abnormal protein buildup or genetic mutations, including those affecting the progranulin gene.
Frontotemporal dementia has no FDA-approved cure, but treatments focus on symptom management through behavioral therapies, antidepressants, and antipsychotic medications, depending on the patient's clinical presentation. In February 2024, the U.S. Food and Drug Administration granted breakthrough therapy designation to latozinemab for frontotemporal dementia with a progranulin gene mutation (FTD-GRN). This monoclonal antibody therapy, developed by Alector and GSK, is under Phase 3 investigation in the INFRONT-3 study.
According to Xinxin Chen et al., 2024, frontotemporal dementia (FTD) accounts for 10–20% of all dementia cases, with a reported prevalence ranging from 3% to 26%. As per the Alzheimer’s Association, around 6.9 million Americans aged 65 and older are currently living with Alzheimer’s dementia, and this figure may rise to 13.8 million by 2060 without effective treatments or preventive measures. As per NHS England, 477,623 individuals had a recorded dementia diagnosis as of January 31, 2024, with a diagnosis rate of 64.4% among those aged 65 and above. These statistics highlight the urgent need for advancements in dementia diagnosis and treatment, particularly for FTD.
This section of the report covers the analysis of frontotemporal dementia drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II at 42%, covers a major share of the total frontotemporal dementia clinical trials. Phase I follows with 26%, indicating a robust early-stage pipeline. Phase III accounts for 16%, showing promising late-stage advancements. This balanced pipeline supports future growth and innovation in the frontotemporal dementia treatment scenario.
The drug molecule categories covered under the frontotemporal dementia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The frontotemporal dementia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for frontotemporal dementia. Gene therapies are emerging as a promising class in the frontotemporal dementia drug pipeline. For instance, AVB-101 by AviadoBio is an investigational gene therapy designed to deliver a functional GRN gene copy directly to the brain. It aims to restore progranulin levels and potentially halt disease progression in patients with frontotemporal dementia with GRN mutations (FTD-GRN).
The EMR report for the frontotemporal dementia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed frontotemporal dementia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in frontotemporal dementia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for frontotemporal dementia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of frontotemporal dementia drug candidates.
AL001, developed by Alector Inc., is currently undergoing a global Phase 3 clinical trial (INFRONT-3) to evaluate its efficacy and safety in individuals at risk for or with frontotemporal dementia due to heterozygous progranulin mutations. The study is assessing AL001, an investigational monoclonal antibody designed to restore progranulin levels, a critical regulator of brain immune activity linked to neurodegeneration. Intravenous administration is being used throughout the 96-week blinded phase.
LY3884963 is currently being evaluated by Prevail Therapeutics in the Phase 1/2 PROCLAIM trial for patients with frontotemporal dementia with progranulin mutations (FTD-GRN). This first-in-human gene therapy is being administered via intra-cisternal injection using the AAV9 vector to deliver a functional GRN gene. The objective is to assess safety, tolerability, and the therapy’s ability to increase progranulin protein levels in the central nervous system.
VES001 is being studied by Vesper Biotechnologies ApS, sponsored by Mads Kjolby, in a Phase 1 trial to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in asymptomatic GRN-FTD patients. The drug, an oral sortilin inhibitor, aims to maintain healthy progranulin levels by preventing its degradation. This open-label study has enrolled six participants across two dose levels over a three-month period.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Frontotemporal Dementia Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for frontotemporal dementia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into frontotemporal dementia collaborations, regulatory environments, and potential growth opportunities.
Upto 30% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share